Related Experiment Video
Updated: Aug 8, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy
Alexandre Detappe1, Sijumon Kunjachan2, Lucie Sancey3
1Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Lyon-1 University, Institut Lumière Matière, CNRS UMR5306, Lyon, France.
Ultra-small silica-based gadolinium nanoparticles (SiGdNP) enhance radiation therapy by improving tumor targeting and reducing healthy tissue damage. Safe systemic administration and renal clearance were demonstrated, supporting their use in MR-guided cancer treatment.
Area of Science:
- Nanomedicine
- Radiotherapy
- Medical Imaging
Background:
- Radiation therapy is crucial for over 50% of cancer patients.
- Collateral damage to healthy tissues and limited therapeutic effects on tumors are significant clinical challenges.
- Need for improved targeted therapies and imaging modalities in oncology.
Purpose of the Study:
- To evaluate ultra-small, renal clearable, silica-based gadolinium chelated nanoparticles (SiGdNP) for simultaneous MR contrast and radiation dose enhancement.
- To assess the efficacy and safety of SiGdNP in preclinical cancer models.
- To explore the translational potential of SiGdNP for MR-guided radiation therapy.
Main Methods:
- Development and characterization of SiGdNP.
- Testing imaging and therapy functionality in cynomolgus monkeys and pancreatic tumor-bearing mice models.
- Evaluation of tumor cell damage (DNA breaks), growth suppression, and survival rates in a human pancreatic xenograft model under clinical radiation therapy.
Main Results:
- SiGdNP demonstrated simultaneous MR contrast and radiation dose enhancement capabilities.
- Significant improvements in tumor cell damage, growth suppression, and overall survival were observed in the pancreatic xenograft model.
- Safe systemic administration and efficient renal clearance of SiGdNP were confirmed in both species.
Conclusions:
- SiGdNP show significant promise as theranostic agents for MR-guided radiation therapy.
- The nanoparticles offer enhanced tumor targeting and therapeutic efficacy while minimizing damage to surrounding healthy tissues.
- These findings support the clinical translation of SiGdNP for improved cancer treatment outcomes.
